Physician profile
Brian Charles Eppright
NPI 1750319364
$1,564.07
in general payments reported to CMS, 2019-2025
14 companies · $231 in 2025
The $231 reported for 2025 was more than what 83% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $34.12 · 2021: $477 · 2022: $88.16 · 2023: $190 · 2024: $103 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $409.39 | 2019-2025 | Bridion |
| Acacia Pharma INC | $283.82 | 2021-2022 | |
| Heron Therapeutics, INC. | $230.14 | 2023-2025 | Zynrelef, Aponvie |
| Pacira Pharmaceuticals Incorporated | $150.74 | 2019-2025 | Exparel |
| Mindray Ds USA, INC. | $131.05 | 2019 | |
| Chiesi USA, INC. | $126.34 | 2019 | |
| Octapharma USA, INC. | $44.56 | 2025 | Fibryga |
| Mallinckrodt Enterprises LLC | $39.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.77 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $27.85 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.20 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $23.73 | 2025 | |
| Covidien LP | $20.10 | 2020 | |
| Edwards Lifesciences Corporation | $19.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Eppright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.